Jeffrey L Lennox

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3384189/publications.pdf

Version: 2024-02-01

87 papers	6,785 citations	76326 40 h-index	58581 82 g-index
87 all docs	87 docs citations	87 times ranked	6268 citing authors

#	Article	IF	Citations
1	Methylprednisolone for Coronavirus Disease 2019 (COVID-19): Was Benjamin Rush Prescient?. Clinical Infectious Diseases, 2021, 72, e382-e383.	5.8	2
2	Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. PLoS Genetics, 2021, 17, e1009464.	3.5	11
3	Antiretroviral Therapyâ€“Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial. Clinical Infectious Diseases, 2020, 71, 1655-1663.	5.8	12
4	Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy. Journal of Neuroimmunology, 2020, 344, 577246.	2.3	5
5	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenzâ€Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	4.7	125
6	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clinical Infectious Diseases, 2019, 68, 1044-1047.	5.8	22
7	Identification of rare HIV-1â€“infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression. JCI Insight, 2019, 4, .	5.0	21
8	T-cell receptor activator of nuclear factor-ÎºB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts. Aids, 2018, 32, 885-894.	2.2	24
9	Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIVâ€Positive and HIVâ€Negative Individuals in VACS (Veterans Aging Cohort Study). Journal of the American Heart Association, 2018, 7, .	3.7	43
10	Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virusâ€“Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical Infectious Diseases, 2018, 67, 1712-1719.	5.8	22
11	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. Journal of NeuroVirology, 2017, 23, 106-112.	2.1	22
12	A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapyâ€“induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clinical Infectious Diseases, 2016, 63, 663-671.	5.8	42
13	Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment. Journal of NeuroVirology, 2016, 22, 816-822.	2.1	8
14	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-NaÃ¯ve Men and Women in the United States. AIDS and Behavior, 2016, 20, 2983-2995.	2.7	5
15	Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infectious Diseases, 2015, 2, ofv085.	0.9	19
16	Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. Clinical Infectious Diseases, 2015, 60, 1842-1851.	5.8	67
17	Anti-Retroviral Therapy Is Associated with Decreased Alveolar Glutathione Levels Even in Healthy HIV-Infected Individuals. PLoS ONE, 2014, 9, e88630.	2.5	27
18	Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection. PLoS Pathogens, 2014, 10, e1004497.	4.7	93

#	Article	IF	Citations
19	Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitorâ€“Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Annals of Internal Medicine, 2014, 161, 461.	3.9	225
20	Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. Journal of Clinical Pharmacology, 2014, 54, 1063-1071.	2.0	19
21	Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. Clinical Infectious Diseases, 2014, 58, 555-563.	5.8	30
22	Executive Summary: Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2014, 59, 1203-1207.	5.8	10
23	Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2014, 59, e96-e138.	5.8	254
24	Metabolomics of Bronchoalveolar Lavage Differentiate Healthy HIV-1-Infected Subjects from Controls. AIDS Research and Human Retroviruses, 2014, 30, 579-585.	1.1	56
25	Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-NaÃ¯ve Patients. Clinical Pharmacokinetics, 2014, 53, 361-371.	3.5	13
26	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infectious Diseases, The, 2013, 13, 587-596.	9.1	119
27	Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 505-508.	2.1	49
28	Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1â€“Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 77-85.	2.1	198
29	The use of HIV-1 integrase inhibitors in antiretroviral naive patients. Current Opinion in HIV and AIDS, 2012, 7, 409-414.	3.8	12
30	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-NaÃ¯ve HIV-1â€“Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. HIV Clinical Trials, 2012, 13, 228-232.	2.0	30
31	A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. AIDS Research and Human Retroviruses, 2012, 28, 1196-1206.	1.1	46
32	Female Genital Tract Shedding of CXCR4-Tropic HIV Type 1 Is Associated with a Majority Population of CXCR4-Tropic HIV Type 1 in Blood and Declining CD4+Cell Counts. AIDS Research and Human Retroviruses, 2012, 28, 1524-1532.	1.1	5
33	Oral sampling and human papillomavirus genotyping in HIVâ€infected patients. Journal of Oral Pathology and Medicine, 2012, 41, 288-291.	2.7	29
34	Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy. Journal of Critical Care, 2012, 27, 51-57.	2.2	41
35	Immune Activation Mediated Change in Alpha-1-Acid Glycoprotein: Impact on Total and Free Lopinavir Plasma Exposure. Journal of Clinical Pharmacology, 2011, 51, 1539-1548.	2.0	26
36	Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1â€“Infected Patients: 156-Week Results From STARTMRK. Clinical Infectious Diseases, 2011, 53, 807-816.	5.8	149

#	Article	IF	Citations
37	HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the Rectum. Journal of Infectious Diseases, 2011, 204, 761-767.	4.0	65
38	Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 972-979.	5.6	52
39	High Prevalence of Persistent Parasitic Infections in Foreign-Born, HIV-Infected Persons in the United States. PLoS Neglected Tropical Diseases, 2011, 5, e1034.	3.0	32
40	Culturally-adapted and audio-technology assisted HIV/AIDS awareness and education program in rural Nigeria: a cohort study. BMC International Health and Human Rights, 2010, 10, 2.	2.5	6
41	Outcomes For ICU Patients With HIV And Severe Sepsis In The HAART Era. , 2010, , .		0
42	Longâ€Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatmentâ€Experienced Patients with Drugâ€Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. Clinical Infectious Diseases, 2010, 50, 605-612.	5.8	196
43	Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1â€"Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 39-48.	2.1	211
44	Predictors of Success with Highly Active Antiretroviral Therapy in an Antiretroviral-Naive Urban Population. AIDS Research and Human Retroviruses, 2010, 26, 133-138.	1.1	37
45	Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women. Aids, 2010, 24, 1361-1366.	2.2	9
46	Abacavir/lamivudine fixed dose combination in the treatment of patients with HIV infection. HIV Therapy, 2009, 3, 19-29.	0.6	1
47	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet, The, 2009, 374, 796-806.	13.7	621
48	Pandemic Influenza: Implications for Programs Controlling for HIV Infection, Tuberculosis, and Chronic Viral Hepatitis. American Journal of Public Health, 2009, 99, S333-S339.	2.7	12
49	Antiretroviral therapy: When to start and which drugs to use. Current Infectious Disease Reports, 2008, 10, 332-339.	3.0	4
50	Pharmacokinetics of an Indinavir-Ritonavir-Fosamprenavir Regimen in Patients with Human Immunodeficiency Virus. Pharmacotherapy, 2008, 28, 74-81.	2.6	3
51	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 339-354.	27.0	699
52	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 355-365.	27.0	498
53	Impaired Hepatitis C Virus (HCV)-Specific Effector CD8 ⁺ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection. Journal of Virology, 2008, 82, 9808-9822.	3.4	93
54	Global HIV/AIDS Medicine. Emerging Infectious Diseases, 2008, 14, 1006b-1007.	4.3	4

#	Article	IF	Citations
55	Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines. Journal of Virology, 2007, 81, 12071-12076.	3.4	135
56	Liver Enzymes Elevation and Immune Reconstitution Among Treatment-NaÃ¯ve HIV-Infected Patients Instituting Antiretroviral Therapy. American Journal of the Medical Sciences, 2007, 334, 334-341.	1.1	33
57	Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection. HIV Clinical Trials, 2007, 8, 86-97.	2.0	47
58	Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twiceâ€Daily to Onceâ€Daily Therapy. Journal of Clinical Pharmacology, 2007, 47, 970-977.	2.0	17
59	A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis. Lancet Infectious Diseases, The, 2006, 6, 742-748.	9.1	205
60	A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIVâ€Specific Immunizations, and Interleukinâ€2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024). Journal of Infectious Diseases, 2006, 194, 1672-1676.	4.0	78
61	Imported Malaria at an Inner-City Hospital in the United States. American Journal of the Medical Sciences, 2005, 329, 6-12.	1.1	32
62	Diversity, Divergence, and Evolution of Cell-Free Human Immunodeficiency Virus Type 1 in Vaginal Secretions and Blood of Chronically Infected Women: Associations with Immune Status. Journal of Virology, 2005, 79, 9799-9809.	3.4	31
63	Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2005, 40, 1559-1585.	5.8	545
64	Specificity of the Antibody Response to the Pneumococcal Polysaccharide and Conjugate Vaccines in Human Immunodeficiency Virus-Infected Adults. Vaccine Journal, 2004, 11, 137-141.	2.6	43
65	Macrolideâ€Resistant Pneumococcal Endocarditis and Epidural Abscess that Develop during Erythromycin Therapy. Clinical Infectious Diseases, 2003, 36, e19-e25.	5.8	20
66	Detection of Infectious Human Immunodeficiency Virus Type 1 in Female Genital Secretions by a Short-Term Culture Method. Journal of Clinical Microbiology, 2003, 41, 4081-4088.	3.9	12
67	A Study of Discontinuing Maintenance Therapy in Human Immunodeficiency Virusâ€"Infected Subjects with DisseminatedMycobacterium aviumComplex: AIDS Clinical Trial Group 393 Study Team. Journal of Infectious Diseases, 2003, 187, 1046-1052.	4.0	44
68	Infrequent Diagnosis of Primary Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 2003, 163, 2097.	3.8	88
69	Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. Aids, 2003, 17, 2025-2033.	2.2	17
70	Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. Aids, 2003, 17, 1102-1104.	2.2	47
71	Increased Survival of Persons with Tuberculosis and Human Immunodeficiency Virus Infection, 1991â€"2000. Clinical Infectious Diseases, 2002, 34, 1002-1007.	5.8	34
72	Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. Aids, 2002, 16, 85-95.	2.2	54

#	Article	IF	Citations
73	The Menstrual Cycle Does Not Affect Human Immunodeficiency Virus Type 1 Levels in Vaginal Secretions. Journal of Infectious Diseases, 2002, 185, 170-177.	4.0	50
74	Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients. Aids, 2002, 16, 1421-1423.	2.2	15
75	Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine, 2001, 20, 545-553.	3.8	133
76	Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. American Journal of Obstetrics and Gynecology, 2001, 184, 279-285.	1.3	75
77	HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. Aids, 2001, 15, 837-845.	2.2	144
78	DisseminatedMycobacterium aviumComplex Disease among Patients Infected with Human Immunodeficiency Virus, 1985â€“2000. Clinical Infectious Diseases, 2001, 33, 1938-1943.	5.8	71
79	Risk ofCryptosporidiumparvumTransmission between Hospital Roommates. Clinical Infectious Diseases, 2000, 31, 947-950.	5.8	31
80	Correlation between Human Immunodeficiency Virus Type 1 RNA Levels in the Female Genital Tract and Immune Activation Associated with Ulceration of the Cervix. Journal of Infectious Diseases, 2000, 181, 1950-1956.	4.0	73
81	Ineffective Platelet Production in Thrombocytopenic Human Immunodeficiency Virusâ€“Infected Patients. Blood, 1998, 91, 3239-3246.	1.4	114
82	Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. Journal of Clinical Microbiology, 1998, 36, 716-720.	3.9	88
83	Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients. Aids, 1996, 10, 619-624.	2.2	42
84	Patterns of Antibody Recognition of Selected Conserved Amino Acid Sequences from the HIV Envelope in Sera from Different Stages of HIV Infection. AIDS Research and Human Retroviruses, 1989, 5, 33-39.	1.1	39
85	HIV Antibody Screening in a General Hospital Population. JAMA - Journal of the American Medical Association, 1987, 257, 2914.	7.4	4
86	Medical care of the HIV-infected surgical patient. , 0, , 307-316.		0
87	HIV infection. , 0, , 282-291.		0